

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF SUPERVISOR

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Yi Jizu (“**Dr. Yi**”) resigned as an employee representative supervisor of the Company with effect from October 31, 2023 due to personal reasons.

Dr. Yi has confirmed that he has no disagreement with the Board and the supervisory committee of the Company (the “**Supervisory Committee**”) and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited.

The Company would like to take this opportunity to express its sincere gratitude to Dr. Yi for his contribution to the Company during his tenure of service.

APPOINTMENT OF SUPERVISOR

The Board is pleased to announce that Ms. Xiao Ying (肖瑩) (“**Ms. Xiao**”) was democratically elected as an employee representative supervisor of the first session of the Supervisory Committee on October 31, 2023. Pursuant to the Company’s articles of association, employee representative supervisors are elected democratically by the general meeting of employee representative, the general meeting of employees or in other ways, and are not subject to the approval of the Shareholders.

The term of office of Ms. Xiao became effective from October 31, 2023 and will expire until the end of the first session of the Supervisory Committee. Ms. Xiao will not receive any remuneration from the Company as an employee representative supervisor.

The biographical details of Ms. Xiao are set out below:

Ms. Xiao was born in November 1988 in Wuhan, Hubei Province, aged 34. She earned her bachelor's degree in labor and social security from Wuhan University of Technology (武漢理工大學) in June 2011. She joined the Company in July 2011 where she consecutively held positions including human resource specialist, human resource supervisor, senior supervisor of the administrative human resource department, deputy manager of the administrative human resource department, and senior manager of the administrative human resource department. She has served as the manager in the strategic development department of the Company since August 2022. Ms. Xiao has also served as a supervisor of two subsidiaries of the Company (namely, Shijiazhuang Shiyou Biotechnology Co., Ltd and Nanjing Youbodi Biotechnology Co., Ltd) since April 2020 and December 2020, respectively.

Ms. Xiao has confirmed that, save as disclosed above, as at the date of this announcement, she (i) did not hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) did not have other major appointments or professional qualifications; (iii) did not have any relationship with any director, supervisor, senior management, substantial shareholder or controlling shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; (iv) did not hold any other positions with the Company or other members of the Group; and (v) did not have any other interests in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, the Board is not aware of other information in respect of Ms. Xiao's appointment as an employee representative supervisor of the Company that is required to be disclosed pursuant to the requirements set out in Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any matter that needs to be brought to the attention of the Shareholders.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei

Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, October 31, 2023

As of the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director, Mr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Liu Dan, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.